Navigation Links
Transdel Pharmaceuticals to Present at Rodman & Renshaw 12th Annual Healthcare Conference
Date:9/7/2010

LA JOLLA, Calif., Sept. 7 /PRNewswire/ -- Transdel Pharmaceuticals, Inc. (OTC Bulletin Board: TDLP) today announced that Transdel management will present a company overview at the Rodman & Renshaw 12th Annual Healthcare Conference in New York City on Monday, September 13, 2010 at 4:05 p.m. Eastern Time.

Interested parties can access a live webcast via the Internet by visiting the Investor Relations section of the Company's Web site at http://www.transdelpharma.com.

About Transdel Pharmaceuticals, Inc.

Transdel Pharmaceuticals, Inc. (OTCBB: TDLP) is a specialty pharmaceutical company developing non-invasive, topically delivered products. The Company's innovative-patented Transdel™ cream formulation technology is designed to facilitate the effective penetration of a variety of products through the tough skin barrier.  Ketotransdel®, the Company's lead pain product, has successfully completed a Phase 3 clinical trial and utilizes the Transdel technology to deliver the active drug, ketoprofen, a non-steroidal anti-inflammatory drug through the skin directly into the underlying tissues where the drug exerts its well-known anti-inflammatory and analgesic effects. The Company intends to leverage its Transdel™ platform technology to expand and create a portfolio of topical products for a variety of indications.  The Company is actively pursuing partnerships with companies to expand its product portfolio for pharmaceutical and cosmetic/cosmeceutical products.  For more information, please visit http://www.transdelpharma.com.

Safe Harbor Statement

The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the Company's interpretation of the results of its Phase 3 clinical trial for Ketotransdel®; the Company's ability to obtain regulatory approval to market Ketotransdel; and the Company's ability to complete additional development activities for products utilizing its proprietary transdermal delivery platform. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company's business, including, without limitation: the outcome of the final analyses of the data from the Phase 3 clinical trial may vary from the Company's initial conclusions; the FDA may not agree with the Company's interpretation of such results or may challenge the adequacy of the Company's clinical trial design or the execution of the clinical trial; the FDA may continue to require the Company to complete additional clinical trials for Ketotransdel® before the Company can submit a 505(b)(2) NDA application; the results of any future clinical trials may not be favorable and the Company may never receive regulatory approval for Ketotransdel®; and the Company's current need to raise additional funding to complete its product development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC's web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.


'/>"/>
SOURCE Transdel Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Transdel Pharmaceuticals to Present at Rodman & Renshaw 10th Annual Global Healthcare Conference
2. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
3. Transdel Pharmaceuticals to Host Conference Call and Webcast on Tuesday, October 6, 2009 to Announce Top-Line Phase 3 Study Results for Lead Topical Pain Drug Ketotransdel(R)
4. Transdel Pharmaceuticals to Present at Two Investor Conferences
5. Transdel Pharmaceuticals Reports First Quarter 2010 Results
6. Transdel Pharmaceuticals Enters into License Agreement with Jan Marini Skin Research for Cosmeceutical Product
7. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
8. ISTA Pharmaceuticals Reports Second Quarter 2008 Financial Results
9. SGX Pharmaceuticals Announces Financial Results for the Three and Six Months Ended June 30, 2008
10. ADVENTRX Pharmaceuticals to Report Second Quarter 2008 Results
11. Merrimack Pharmaceuticals Initiates Enrollment in a Phase 1 Study of MM-121, an ErbB3 Antagonist
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... SPRING, Md. and RESEARCH TRIANGLE ... Therapeutics Corporation (NASDAQ: UTHR ) announced today ... Executive Officer, of United Therapeutics will provide an overview ... Bank 41 st Annual Health Care Conference. ... 5, 2016, at 10:00 a.m. Eastern Time, and can ...
(Date:4/27/2016)... ... 27, 2016 , ... PathSensors, Inc., a leading environmental testing ... will assist PathSensors in expanding the use of the company’s CANARY® technology in ... platform for the detection of harmful pathogens, including a number of bacteria, viruses, ...
(Date:4/27/2016)... ... ... Global Stem Cells Group and the University of Santiago Biotechnology Lab have ... for potential stem cell protocol management for 2016 – 2020. , In 2015, ... establish a working agenda and foster initiatives to promote stem cell research and development ...
(Date:4/26/2016)... ... April 27, 2016 , ... ... Roca Rothgerber Christie LLP as an associate in the firm’s Intellectual Property practice ... electrical, mechanical and electromechanical patent applications. He has an electrical engineering and computer ...
Breaking Biology Technology:
(Date:4/28/2016)... GOTHENBURG, Sweden , April 28, 2016 ... 1,491.2 M (139.9), up 966% compared with the first quarter of ... Operating profit totaled SEK 589.1 M (loss: 18.8) and the operating ... SEK 7.12 (loss: 0.32) Cash flow from operations was ... , The 2016 revenue guidance is unchanged, SEK 7,000-8,500 M. ...
(Date:4/19/2016)... 2016 The new GEZE SecuLogic ... web-based "all-in-one" system solution for all door components. It ... the door interface with integration authorization management system, and ... The minimal dimensions of the access control and the ... installations offer considerable freedom of design with regard to ...
(Date:4/14/2016)... April 14, 2016 BioCatch ... Detection, today announced the appointment of Eyal Goldwerger ... role. Goldwerger,s leadership appointment comes at a ... of the deployment of its platform at several of ... technology, which discerns unique cognitive and physiological factors, is ...
Breaking Biology News(10 mins):